AACR 2022 -- Bladder cancer (BC) is the thirteenth leading cause of cancer-related deaths. Five checkpoint immunotherapies that target the PD-1/PD-L1 axis are FDA approved, and gene- and protein-based approaches are helping to identify new combination treatment strategies for therapeutic intervention.

AACR 2022 -- T cells engineered to express Chimeric Antigen Receptors (CARs) through transduction with a lentiviral vector represent an effective strategy to specifically eliminate cancerous cells from a patient. Anti-CD19 single chain variable fragment (ScFv) is the extracellular, antigen-binding domain.

AACR 2022 -- Labcorp has employed 3D model systems co-developed with zPREDICTA to create preclinical models to address the increasing relevance of 3D in vitro models. These organ-specific models support tumor cell growth and mimic the composition and architecture of both solid tumors and hematological malignancies.

AACR 2022 -- Syngeneic mouse tumor models are widely used to demonstrate activity of novel anti-cancer immunotherapies. RM-1 is a murine prostate cancer cell line derived from a Ras/Myc-induced prostate cancer that grows aggressively, is nonimmunogenic and androgen independent.

AACR 2022 -- In the preclinical oncology setting, the B16-F10 syngeneic melanoma model is commonly used but is highly refractory to most immunomodulators, limiting the applicability of this model.

The Delivery Director role is a key component of the Labcorp Drug Development Operating Model for clinical trials. One is assigned to each trial and is a senior leader who improves the delivery through experience, insight and connections within the business.

With an integrated, global safety team of over 2,700 across 20 delivery centers, we provide end-to-end safety solutions that span the entire product life cycle of drugs, medical devices, combination products and vaccines from clinical phases through commercialization.

Labcorp Drug Development continues to support the full-service agreement with ongoing recruitment, data management, biostatistics and clinical studies reports following an integrated project schedule.